Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis.
Atezolizumab
Breast cancer
Cholangitis
Immune-related adverse event
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
09
01
2022
accepted:
24
05
2022
pubmed:
22
6
2022
medline:
2
8
2022
entrez:
21
6
2022
Statut:
ppublish
Résumé
Cholangitis has been reported as an immune-related adverse event, although it rarely occurs. Here we report a case of cholangitis due to atezolizumab in a 77-year-old woman who had been treated with atezolizumab and nab-paclitaxel for breast cancer and lung metastasis. On the seventh cycle, she presented with fever and epigastric pain, and computed tomography and endoscopic ultrasound showed slight wall thickening of the common bile duct, and transpapillary bile duct biopsy was performed. Pathologically, CD8
Identifiants
pubmed: 35729450
doi: 10.1007/s12328-022-01651-3
pii: 10.1007/s12328-022-01651-3
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
818-821Informations de copyright
© 2022. Japanese Society of Gastroenterology.
Références
Nabeshima S, Yamasaki M, Matsumoto N, et al. Atezolizumab-induced sclerosing cholangitis in a patient with lung cancer: a case report. Cancer Treat Res Commun. 2021;26: 100270.
doi: 10.1016/j.ctarc.2020.100270
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
doi: 10.1016/j.immuni.2013.07.012
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.
doi: 10.1056/NEJMoa1809615
Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020;26:353–65.
doi: 10.3748/wjg.v26.i3.353
Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965–73.
doi: 10.1038/s41379-018-0013-y
Stuart L, Lambourne B, Turner P, et al. Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma. Hepatology. 2020;71:2164–6.
doi: 10.1002/hep.31089
Tang J, Zhao GX, Deng SS, et al. Rare common bile duct metastasis of breast cancer: a case report and literature review. World J Gastrointest Oncol. 2021;13:147–56.
doi: 10.4251/wjgo.v13.i2.147
Iwai Y, Terawaki S, Ikegawa M, et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003;198:39–50.
doi: 10.1084/jem.20022235